COVID-19 drained 8% of market value from Big Pharma in Q1, but Gilead and Regeneron soared: report

Red stock market line indicating recession and superimposed dollar bill
The Dow Jones industrial average had its worst first-quarter performance ever due to the COVID-19 pandemic. (Corlaffra/Shutterstock)

What happens when a biopharma company responds to a pandemic with a well thought out, scientifically sound plan to address it immediately?

That company’s stock soars while the rest of the top players in biopharma are losing a whopping 7.9% in combined market value due to COVID-19.

At least, that’s what happened in the first quarter for Gilead Sciences and Regeneron, which saw their market caps grow 14.5% and 32.5%, respectively. In fact, they were two of just seven companies among the top 20 pharma players by market cap that charted gains as the COVID-19 pandemic swept across the globe. The aggregate market cap of the top 20 players dropped to $2.6 trillion, according to a new report from GlobalData.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Regeneron’s gain isn’t entirely surprising, given how early it jumped in with an ambitious plan to tackle COVID-19. In mid-March, Regeneron announced it had isolated antibodies from mouse models and human survivors of COVID-19 that could neutralize the virus. Now, it’s preparing an antibody cocktail for a summer clinical trial.

But that wasn’t Regeneron’s only strategy for combating the pandemic. It was simultaneously working with longtime partner Sanofi to repurpose their shared IL-6 inhibitor Kevzara as a COVID-19 treatment. By the end of March, Kevzara was being tested in two pivotal coronavirus clinical trials.

RELATED: Gilead turbocharges production of COVID-19 hopeful remdesivir

Gilead has also garnered kudos for hustling its experimental treatment remdesivir into clinical trials—and into hospitals for use on a compassionate basis in patients fighting COVID-19. Earlier this month, Gilead CEO Daniel O'Day said the company had slashed the manufacturing timeline for the drug and ramped up production so it could churn out 1 million remdesivir treatment courses by the end of the year.

Roche, which is testing its rheumatoid arthritis drug Actemra in COVID-19, had a 3.6% gain in market value in the first quarter. The drug was already performing well: Actemra sales jumped 30% to CHF 666 million ($687 million) in the first quarter, Roche said yesterday.

But not all of the COVID-19 hopefuls were rewarded by investors in the first quarter. Interestingly, longtime Regeneron partner Sanofi saw its market cap drop nearly 12% despite the fact that it stands to gain if Kevzara succeeds in COVID-19. What’s more, the company recently teamed with GlaxoSmithKline to develop a vaccine against the disease. Still, Sanofi is grappling with other challenges, not the least of which is pressure from Wall Street to freshen up its pipeline even more.

RELATED: Inside Regeneron's R&D war room, sleepless nights and 'esprit de corps' in hunt for COVID-19 therapy

A few other prominent COVID-19 players suffered market-cap losses in the first quarter. They included Pfizer (down 16.5%) and Johnson & Johnson (down 10%). Pfizer is about to launch a COVID-19 vaccine trial with BioNTech, but threats to its core business—like the patent expiration on pain drug Lyrica—caused its revenues to fall 4% last year.

As for J&J, which is also racing to develop a COVID-19 vaccine, it’s the biggest pharma company by revenue and market cap, but it’s also facing its share of challenges. One of its top sellers, Remicade, has been trounced by generic competition, as has its prostate cancer drug Zytiga. J&J’s nagging legal issues—which include opioid trial losses and the ongoing talc lawsuits—haven’t helped soothe investors.

The good news for Big Pharma in the first quarter is that the cumulative 7.9% drop in market cap actually wasn’t as bad as it might seem, GlobalData said. The Dow Jones industrial average, after all, had its worst first-quarter performance ever, losing 23%.

“The reversal of fortune, due to COVID-19, may seem dramatic due to these companies’ long-term growth, however, the effect on the pharmaceutical industry has been mild compared to other industries,” Peter Shapiro, senior director of drugs and business fundamentals for GlobalData, said in the report.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.